high5immunology.tv | IBD | ECCO 2022

Therapeutic Concepts: Discussions

EARNEST, DIVERGENCE 2

ECCO 2022

Light at the end of the Pouchitis track

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

VEGA

ECCO 2022

Combination trials open a new door in IBD treatment

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SPARE

ECCO 2022

Is the continuation of combination therapy the key to…

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SELECTION, GALAXI 1, LUCENT-1

ECCO 2022

Combined endpoints as new therapy goals

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SERENITY

ECCO 2022

The potential of histology in Crohn´s disease and how…

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

RESTORE-UC

ECCO 2022

Microbiota manipulation: Still a lot to learn

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Therapeutic Concepts – ENG

SPARE

ECCO 2022

SPARE study in ECCO 2022

Iris Dotan, MD

RESTORE-UC

ECCO 2022

A negative control trial for FMT in UC

David Laharie, MD

SPARE

ECCO 2022

How to deescalate treatment in CD?

David Laharie, MD

NOR-DRUM B

ECCO 2022

A new opportunity for proactive TDM disease control

Massimo Claudio Fantini, MD

SEAVUE / STARDUST

ECCO 2022

Ustekinumab for fistulizing disease

Peter Irving, MD

NOR-DRUM B

ECCO 2022

Proactive TDM or SOC for monitoring infliximab…

Gerassimos Mantzaris, MD

VEGA

ECCO 2022

Combination of biologics - finally arrived in IBD!?

Alexander Moschen, MD

DIVERGENCE 2

ECCO 2022

Filgotinib for fistulizing disease

Peter Irving, MD

RESTORE-UC

ECCO 2022

FMT in UC - still far away from the success story

Piotr Eder, MD

NOR-DRUM B

ECCO 2022

Proactive TDM

Peter Irving, MD

VEGA

ECCO 2022

Will we improve the management of IBD by combining…

Matthieu Allez, MD

VEGA

ECCO 2022

Combination of biologics

Silvio Danese, MD

VEGA

ECCO 2022

Combination with different classes of drugs in moderate…

Fernando Magro, MD

VEGA

ECCO 2022

The first combination therapy trial

Massimo Claudio Fantini, MD

RESTORE-UC

ECCO 2022

FMT is not a promising option for UC patients

Gerhard Rogler, MD

SPARE

ECCO 2022

Is stopping of therapy an option in CD?

Gerhard Rogler, MD

ECCO 2022

Is the speedity of the steroid tapering important…

Gerassimos Mantzaris, MD

SPARE

ECCO 2022

Infliximab withdrawl leeds to a higher risk of…

James Lindsay, MD

SPARE

ECCO 2022

When to withdraw therapy in crohn's disease?

Axel Dignaß, MD

ECCO 2022

The interleukin-17 conundrum

Alexander Moschen, MD

SPARE

ECCO 2022

Withdrawal of infliximab or anti-metabolite therapy in…

Fernando Magro, MD

Therapeutic Concepts – ITA/GER/AUT/GRE/FRA/POL/ISR/SUI

SPARE

ECCO 2022

Ist der Therapiestopp eine Option in CD?

Gerhard Rogler, MD

ECCO 2022

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…

Gerassimos Mantzaris, MD

RESTORE-UC

ECCO 2022

Un essai négatif sur la transplantation de microbiote…

David Laharie, MD

ECCO 2022

Das Interleukin-17 Rätsel

Alexander Moschen, MD

VEGA

ECCO 2022

Allons nous améliorer la prise en charge des MICI en…

Matthieu Allez, MD

VEGA

ECCO 2022

Combinazione di biologici

Silvio Danese, MD

NOR-DRUM B

ECCO 2022

Una nuova opportunità per i TDM nel controllo proattivo…

Massimo Claudio Fantini, MD

SPARE

ECCO 2022

Wann Beendigung von Infliximab oder Immunmodulatoren…

Axel Dignaß, MD

RESTORE-UC

ECCO 2022

FMT ist kein vielversprechender Ansatz für UC-Patienten

Gerhard Rogler, MD

VEGA

ECCO 2022

Kombination von Biologika - endlich bei IBD…

Alexander Moschen, MD

NOR-DRUM B

ECCO 2022

Προληπτική μέτρηση των θεραπευτικών επιπέδων του…

Gerassimos Mantzaris, MD

SPARE

ECCO 2022

מחקר SPARE ב ECCO 2022

Iris Dotan, MD

RESTORE-UC

ECCO 2022

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Piotr Eder, MD

VEGA

ECCO 2022

Il primo trial di terapia biologica di combinazione

Massimo Claudio Fantini, MD

SPARE

ECCO 2022

Du nouveau sur l’allégement thérapeutique au cours de…

David Laharie, MD

Targeting Safety: Discussions

ECCO 2022

Which IBD patients have a higher risk of safety…

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

CLARITY IBD

Ecco 2022

COVID-19: still a moving target!

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

VEGA

ECCO 2022

Is combination therapy safe?

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

OCTAVE / RIVETING, DIVERGENCE 2, U-ACHIEVE

ECCO 2022

Can we translate rheumatoid arthritis to ulcerative…

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

ECCO 2022

Inflammatory bowel disease and cancer risk

A. Dignaß, S. Schreiber, D. Laharie, P. Eder, J. Lindsay, A. Armuzzi

Targeting Safety – ENG

VEGA

ECCO 2022

A touch of the near future in IBD treatment

Alessandro Armuzzi, MD

ECCO 2022

The heart is apparently safe with continuous Ozanimod…

Alessandro Armuzzi, MD

MECONIUM

ECCO 2022

Breastmilk is tuning IBD risk

Alexander Moschen, MD

Targeting Safety – ITA/AUT

MECONIUM

ECCO 2022

Muttermilch beeinflusst das IBD-Risiko

Alexander Moschen, MD

VEGA

ECCO 2022

Uno sguardo al prossimo futuro nel trattamento delle…

Alessandro Armuzzi, MD

ECCO 2022

Il cuore sembra essere apparentemente al sicuro durante…

Alessandro Armuzzi, MD

Targeting Efficacy: Discussions

ECCO 2022

Mucosal healing: Will efficacy data translate into real…

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

SEAVUE / STARDUST, DIVERGENCE 2

ECCO 2022

Fistulizing Crohn‘s disease - new treatment options…

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

VEGA, GALAXI 1, QUASAR, LUCENT-1

ECCO 2022

The race is on IL-23 – exciting data for CD and UC

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

EARNEST, VEDOKIDS, VEDOIBD

ECCO 2022

Vedolizumab: promising data for pouchitis and IBD in…

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude, S. Schreiber

U-ACHIEVE / U-ACCOMPLISH, SELECTION

ECCO 2022

Efficacy update on JAKis

G. Mantzaris, M. Allez, M. C. Fantini, A. Dignaß, P. Irving, C. J. van der Woude

Targeting Efficacy – ENG

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Selective IL-23 blockade

Axel Dignaß, MD

U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING

ECCO 2022

JAK inhibition

Axel Dignaß, MD

EARNEST

ECCO 2022

Vedolizumab in chronic pouchitis - a new chapter in…

Piotr Eder, MD

EARNEST

ECCO 2022

Vedolizumab is effective in chronic pouchitis after…

James Lindsay, MD

ECCO 2022

Upadacitinib - will it be the game changer in UC?

Piotr Eder, MD

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Anti-IL-23 - a turning point?

Stefan Schreiber, MD

EARNEST

ECCO 2022

Great news on pouchitis treatment - vedolizumab…

Fernando Magro, MD

ECCO 2022

New ways of treatment

Fernando Gomollón, MD

GALAXI 1

ECCO 2022

Guselkumab as maintenace treatment in Crohn's Disease

Silvio Danese, MD

EARNEST

ECCO 2022

New opportunity in pouchitis treatment

Massimo Claudio Fantini, MD

Targeting Efficacy – ITA/GER/ESP/POL

U-ACHIEVE / U-ACCOMPLISH, SELECTION / SELECTIONLTE, DIVERGENCE 2, OCTAVE / RIVETING

ECCO 2022

JAK-Inhibition

Axel Dignaß, MD

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Anti-IL-23 - eine Zeitenwende?

Stefan Schreiber, MD

ECCO 2022

Nuevos caminos en el tratamiento

Fernando Gomollón, MD

GALAXI 1

ECCO 2022

Guselkumab come terapia di mantenimento

Silvio Danese, MD

EARNEST

ECCO 2022

Wedolizumab w pouchitis - początek nowego rozdziału w…

Piotr Eder, MD

EARNEST

ECCO 2022

Una nuova opportunità nel trattamemto della pouchite

Massimo Claudio Fantini, MD

QUASAR, GALAXI 1, LUCENT-1, FORTIFY

ECCO 2022

Selektive IL-23 Blockade

Axel Dignaß, MD

ECCO 2022

Upadacitinib - nowy lek, duże nadzieje

Piotr Eder, MD

Treatment Goals – ENG

SELECTION

ECCO 2022

Disease control is possible!

Stefan Schreiber, MD

U-ACHIEVE

ECCO 2022

Patient relevant outcomes also show efficacy of…

James Lindsay, MD

EPIMAD registry

ECCO 2022

Natural history of anal ulcerations in pediatric-onset…

David Laharie, MD

ECCO 2022

New goals for IBD

Fernando Gomollón, MD

SELECTION

ECCO 2022

New therapeutic goals in UC

Fernando Magro, MD

LUCENT-1 and others

ECCO 2022

New therapy goals: urgency and disease clearance

Axel Dignaß, MD

SERENITY

ECCO 2022

Histological findings in mirikizumab treatment

Fernando Magro, MD

Treatment Goals – GER/FRA/ESP

ECCO 2022

Nuevas objetivos en las EII

Fernando Gomollón, MD

SELECTION

ECCO 2022

Disease Control ist möglich!

Stefan Schreiber, MD

EPIMAD registry

ECCO 2022

Histoire naturelle de la maladie de Crohn ano-périnéale…

David Laharie, MD

LUCENT-1 and others

ECCO 2022

Urgency und Disease Clearance

Axel Dignaß, MD

Targeting COVID-19 – ENG

VIP, CLARITY IBD

ECCO 2022

The efficacy of COVID-19 vaccines in IBD - what's new?

Piotr Eder, MD

VIP, RECOVERI

ECCO 2022

COVID-19 in patients with IBD stratified acc. to…

Iris Dotan, MD

Targeting COVID-19 – POL/ISR

VIP, CLARITY IBD

ECCO 2022

Skuteczność szczepień przeciw COVID-19 w IBD - nowe…

Piotr Eder, MD

VIP, RECOVERI

ECCO 2022

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי…

Iris Dotan, MD

Diagnostics and Prediction – ENG

TRUST BEYOND

ECCO 2022

Ultrasound as a predictor of treatment response

Axel Dignaß, MD

ECCO 2022

Point of Care Testing / AI / Telemedicine

Axel Dignaß, MD

Diagnostics and Prediction – GER

TRUST BEYOND

ECCO 2022

Ultraschall als Prädiktor des Therapieansprechens

Axel Dignaß, MD

ECCO 2022

Digitale Tools, KI und Telemedizin

Axel Dignaß, MD

Varia – ENG

EITOS, VERSUS-CD, DUMBO

ECCO 2022

Spanish women leading contribution to ECCO 2022

Fernando Gomollón, MD

ECCO 2022

ECCO guidelines on pregnancy

Christien Janneke van der Woude, MD

Varia – NLD/ESP

EITOS, VERSUS-CD, DUMBO

ECCO 2022

Las mujeres lideran la contribución española a la ECCO…

Fernando Gomollón, MD

ECCO 2022

ECCO Richtlijnen zwangerschap

Christien Janneke van der Woude, MD